| Literature DB >> 26832213 |
Arlene Fink1, Lorna Kwan, Dan Osterweil, Jenna Van Draanen, Alexis Cooke, John C Beck.
Abstract
BACKGROUND: Older adults can experience unfavorable health effects from drinking at relatively low consumption levels because of age-related physiological changes and alcohol's potentially adverse interactions with declining health, increased medication-use and diminishing functional status. At the same time, alcohol use in older adults may be protective against heart disease, stroke, and other disorders associated with aging. We developed "A Toast to Health in Later Life! Wise Drinking as We Age," a web-based educational intervention to teach older adults to balance drinking risks and benefits.Entities:
Keywords: alcohol; education; elderly; older adults; online alcohol education; web-based
Year: 2016 PMID: 26832213 PMCID: PMC4754533 DOI: 10.2196/resprot.4545
Source DB: PubMed Journal: JMIR Res Protoc ISSN: 1929-0748
Figure 1Screenshot from "A Toast to Health in Later Life! Wise Drinking as We Age". Content for one instructional objective.
Figure 2Sample question from the Alcohol-Related Problems Survey (ARPS).
Figure 3Participant flow chart.
Quantity and frequency of drinking.
| Quantity/Frequency | Intervention | Control | |||||
|
|
| Baseline (n=49) | Follow-up (n=49) |
| Baseline (n=47) | Follow-up (n=47) |
|
|
|
|
|
|
|
|
|
|
|
| 3 or more drinks per daya | 5 (10.2) | 2 (4.1%) | .31b | 1 (2.1%) | 3 (6.4%) | .56bd |
|
| 2 drinks per day | 9 (18.4) | 14 (28.6%) |
| 16 (34.0%) | 18 (38.3% ) |
|
|
| 1 drink or less | 35 (71.4) | 33 (67.4%) |
| 30 (63.8%) | 26 (55.3%) |
|
|
|
|
|
|
|
|
|
|
|
| Drinks daily or almost dailyc | 15 (30.6) | 14 (28.6) | .99b | 18 (38.3) | 18 (38.3) | .67d |
|
| Drinks 4 or 5 times a week | 4 (8.2) | 5 (10.2) |
| 6 (12.8) | 9 (19.2) |
|
|
| Drinks 2 or 3 times a week or less | 30 (61.2) | 30 (61.2) |
| 23 (48.9) | 20 (42.6) |
|
a No differences in quantity between the groups at baseline (P=.09) or follow-up (P=.54).
b Fisher’s exact test
c No differences in frequency between groups at baseline (P=.46) or follow-up (P=.17).
d P-values for the paired data analyses (Bowker's test of symmetry) between baseline and follow-up for quantity is .26 for the intervention group and .26 for the control group; for frequency, the P-value is .80 for the intervention group and .36 for the control group.
Participants who passed and failed to meet NIAAA’sa recommended weekly limits.b
| Result | Intervention | Control | ||||
| Baseline(n=49) | Follow-up(n=49) |
| Baseline (n=47) | Follow-up (n=47) |
| |
| NIAAA failc | 15 (30.6) | 15 (30.6) | .99d | 20 (42.6) | 23 (48.9) | .53d |
| NIAA pass | 34 (69.4) | 34 (69.4) |
| 27 (57.4) | 24 (51.1) |
|
a NIAAA: The National Institute on Alcohol Abuse and Alcoholism
b 7 drinks weekly for all women and men 65 years of age and older; 14 drinks weekly for men under 65 years of age
c No differences between groups at baseline (P=.22) or follow-up (P=.67).
d P-values for the paired sample analyses (McNemar’s test) between baseline and follow-up are .99 (100% agreement) for the intervention group and .26 for the control group.
Drinking risk.
| Risk level | Intervention | Control | ||||
|
| Baselinea (n=49) | Follow-upa (n=49) |
| Baselinea (n=47) | Follow-upa (n=47) |
|
| Harmfulc | 13 (26.5) | 16 (32.7) | .63 | 18 (38.3) | 21 (44.7) | .74b |
| Hazardousd | 9 (18.4) | 6 (12.2) |
| 13 (27.7) | 10 (21.3) |
|
| Non-hazardouse | 27 (55.1) | 27 (55.1) |
| 16 (34.0) | 16 (34.0) |
|
a No differences in risk category at baseline (P=.12) or follow-up (P=.11).
b P-values for the paired data analyses (Bowker’s test of symmetry) between baseline and follow-up are .73 for the intervention and .72 for the control group.
c Problems are likely
d At-risk for problems
e No known risks
Participants reported change in drinking in the past 4 weeks.
|
| Baseline |
| Follow-up |
| ||
|
| Baselinea (n=49) | Follow-upa (n=47) | .74 | Baselinea (n=49) | Follow-upa (n=47) | .02b |
| Less | 6 (12.2) | 4 (8.5) |
| 13 (26.3) | 4 (8.5) |
|
| Same | 0 (0.0) | 0 (0.0) |
| 0 (0.0) | 0 (0.0) |
|
| More | 43 (87.8) | 36 (73.5) |
| 37 (73.5) | 43 (91.5) |
|
aThe Fisher exact test P value for the control group from baseline to follow-up is .99.
b P value for the paired data analyses (McNemar’s test or Bowker’s test of symmetry) is .02 for the intervention group from baseline to follow-up; for the control group, the P-value is .99.
Intervention participants’ report on the usability of “A Toast to Health in Later Life!” (n=49).
| Usability characteristic | n (%) | |
|
|
|
|
|
| Rated “No difficulty” | 36 (73.5) |
|
| Rated “Little difficulty” | 10 (20.4) |
|
|
|
|
|
| Rated “A great deal” | 32 (65.3) |
|
| Rated “A little” | 15 (30.6) |
|
|
|
|
|
| Rated “Very” | 12 (24.5) |
|
| Rated “Somewhat” | 25 (51.0) |
|
|
|
|
|
| Rated “Definitely” | 18 (36.7) |
|
| Rated “Probably” | 20 (40.8) |
|
|
|
|
|
| Rated “Definitely” | 30 (61.2) |
|
| Rated “Probably” | 16 (32.7) |
|
|
|
|
|
| Rated “Some” | 32 (65.3) |
|
| Rated “Much” | 1 (2.0) |
Intervention and control participant baseline characteristics.
|
| Intervention Group (n=49) | Control Group (n=47) |
|
| Sex (Female) | 34 (69.4) | 33 (70.2) | .93 |
| Education, % College or more | 39 (79.6) | 41 (87.2) | .33 |
| Health status, % Excellent or very good | 37 (75.5) | 31 (66.0) | .30 |
| Race: White | 44 (89.8) | 42 (89.4) | .99a |
| Ethnicity: Hispanic | 3 (6.1) | 3 (6.4) |
|
| Doctor ever told you have hypertension | 21 (42.9) | 21 (44.7) | .86 |
| Doctor ever told you have breast cancer (♀) | 4 (11.8) | 5 (15.2) | .74a |
| Doctor ever told you have depression | 6 (12.2) | 8 (17.0) | .51 |
| Falls were a problem in the past 12 months | 6 (12.5) | 8 (17.0) | .53 |
| Daily NSAIDsc | 13 (26.5) | 12 (25.5) | .91a |
| Daily high blood pressure medicine | 20 (40.8) | 17 (36.2) | .64 |
| Daily take an anticoagulant | 1 (2.1) | 1 (2.2) | .99a |
| Weekly sedative, narcotic or tranquillizer | 11 (22.5) | 8 (17.0) | .50 |
| Ever drank 4 or more drinks at one sitting in past 12 months | 8 (16.3) | 11 (23.4) | .38 |
a Fisher exact test
b Wilcoxon-Mann-Whitney test
c NSAID: Nonsteroidal anti-inflammatory drug